Navigation Links
Genetic signatures provide new direction in liver cancer

Vienna, Austria, Friday 16 April: Results of an international clinical study conducted in Europe and the US presented today at the International Liver CongressTM 2010, the Annual Meeting of the European Association for the Study of Liver in Vienna, Austria, have identified a genomic portrait able to predict recurrence in hepatocellular carcinoma (HCC), the fifth most common cancer in men .

HCC is a primary cancer of the liver. Worldwide, it accounts for approximately 5.4% of all cancers1 and it is the third cause of cancer-related death with more than 660,000 deaths per year1. Only around 20-30% of patients are treated with curative treatments, including resection and local ablation, but recurrence complicated the outcome in more than two thirds of these cases .

Results of this study identified two gene signatures- one coming from the tumor and the other from the cirrhotic liver - able to identify patients with poor disease outcome. The study concluded that these genetic tools can ultimately be used to select patients for preventive therapies. In addition, specific genes included in these signatures should be evaluated as potential targets for adjuvant treatment, following surgical intervention in HCC patients.

Dr Josep Llovet, Professor from the Hospital Clinic of Barcelona-IDIBAPS and Mount Sinai School of Medicine in New York, who led the study and highlighted this topic at EASL's official press conference said, "The results of our study demonstrate the potential that molecular classification offers to future clinical management of diseases such as HCC. By successfully identifying certain genomic signatures that clearly predict both overall and early recurrence of HCC post-surgery, we now have a clearer focus for future research into therapeutic options that may in time improve patients' chances of survival".

The study was presented at EASL by Augusto Villanueva, MD member of the International HCC Genomic Consortium. The genomic profiles of 287 HCC patients using whole-genome gene expression platforms were analysed. The study focussed on patients with early HCC (n=257, principally male 189/257, with a mean age of 64) with tumoral tissue (n=257) and adjacent non-tumoural cirrhotic tissue (n=209). Patients were on average followed up after 46 months there were 167 recurrences (64%) and 89 deaths (34%). In total, 20 gene signatures were evaluated with reported ability to predict survival and or recurrence of HCC. Genomic signatures from the tumour (Proliferation-G3) and adjacent tissue (with poor prognosis) of patients with HCC were identified as important in predicting both overall and early recurrence in HCC. The multinodularity gene signature was also identified as a predictor for HCC recurrence while tumor size was identified as predictor for early recurrence.


Contact: Isabelle Scali
European Association for the Study of the Liver

Related biology news :

1. Does the desire to consume alcohol and tobacco come from our genetic makeup?
2. Diverse genetic abnormalities lead to NF-κB activation in multiple myeloma
3. Many parents at-risk for cancer disclose genetic test results to children
4. Genetics determine optimal drug dose of common anticoagulant
5. Claims of sex-related differences in genetic association studies often not properly validated
6. American College of Medical Genetics responds to new FDA labeling decision for warfarin
7. UNC study questions FDA genetic-screening guidelines for cancer drug
8. Genome study shines light on genetic link to height
9. Selexis Announces Advanced Approach to Maximize Power of Genetic Elements for Rapid Development of High Performance Cell Lines
10. Genes, Environment and Health Initiative invests in genetic studies, environmental monitoring
11. Rutgers Genetics receives $7.8 million for autism research
Post Your Comments:
(Date:11/2/2015)... PARK, Calif. , Nov. 2, 2015  SRI ... $9 million to provide preclinical development services to the ... the contract, SRI will provide scientific expertise, modern testing ... wide variety of preclinical pharmacology and toxicology studies to ... --> The PREVENT Cancer Drug Development ...
(Date:10/29/2015)... Oct. 29, 2015  Rubicon Genomics, Inc., today ... distribution of its DNA library preparation products, including ... new ThruPLEX Plasma-seq kit. ThruPLEX Plasma-seq has been ... of NGS libraries for liquid biopsies--the analysis of ... prognostic applications in cancer and other conditions. Eurofins ...
(Date:10/27/2015)... , Oct. 27, 2015 In the present ... of concern for various industry verticals such as banking, ... to the growing demand for secure & simplified access ... ,sectors, such as hacking of bank accounts, misuse of ... equipment such as PC,s, laptops, and smartphones are expected ...
Breaking Biology News(10 mins):
(Date:11/27/2015)... ... 2015 , ... Pittcon is pleased to announce the 2016 ... symposia, oral sessions, workshops, awards, and posters. The core of the Technical ... as, but not limited to, biotechnology, biomedical, drug discovery, environmental, food science, fuels/energy, ...
(Date:11/25/2015)... -- PharmAthene, Inc. (NYSE MKT: PIP) announced  today that its ... (Rights Plan) in an effort to preserve the value ... 382 of the Internal Revenue Code (Code). ... its NOLs could be substantially limited if the Company ... of the Code. In general, an ownership change occurs ...
(Date:11/25/2015)... 25, 2015 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ:  AEZS; ... and prospects remain fundamentally strong and highlights the ... recently received DSMB recommendation to continue the ZoptEC ... of the final interim efficacy and safety data ... in men with heavily pretreated castration- and Taxane-resistant ...
(Date:11/24/2015)... LUMPUR, Malaysia , Nov. 24, 2015 /PRNewswire/ ... global contract research organisation (CRO) market. The trend ... result in lower margins but higher volume share ... increased capacity and scale, however, margins in the ... Research Organisation (CRO) Market ( ), ...
Breaking Biology Technology: